ProQR Therapeutics (PRQR) Receivables - Other (2013 - 2026)
ProQR Therapeutics (PRQR) posted Receivables - Other of $372297.1 for Q1 2026, up 2.18% sequentially from $364345.6 in Q4 2025, and down 79.48% YoY from $1.8 million in Q1 2025.
ProQR Therapeutics (PRQR) Receivables - Other (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Receivables - Other for 13 years, with the latest figure at $372297.1 in Q1 2026.
- Quarterly Receivables - Other fell 79.48% year-over-year to $372297.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $372297.1 (down 79.48% YoY) and the FY2025 annual result came in at $364345.6, down 59.17% from the prior year.
- Receivables - Other grew to $372297.1 in Q1 2026 per PRQR's latest filing, from $364345.6 in the prior quarter.
- Over five years, Receivables - Other peaked at $4.4 million in Q2 2024 and troughed at $364345.6 in Q4 2025.
- A 5-year average of $1.6 million and a median of $1.2 million in 2025 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2026: Receivables - Other soared 109.51% in 2023, then plunged 79.48% in 2026.
- Over 5 years, Receivables - Other stood at $382592.8 in 2022, then jumped by 109.51% to $801575.2 in 2023, then grew by 11.32% to $892277.2 in 2024, then slumped by 59.17% to $364345.6 in 2025, then climbed by 2.18% to $372297.1 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $372297.1, $364345.6, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 372,297.12 |
| Mar 31, 2026 | 372,297.12 |
| Dec 31, 2025 | 364,345.62 |
| Dec 31, 2025 | 364,345.62 |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 892,277.16 |
| Dec 31, 2024 | 892,277.16 |
| Sep 30, 2024 | 845,629.02 |
| Sep 30, 2024 | 845,629.02 |
| Jun 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 801,575.23 |
| Dec 31, 2023 | 801,575.23 |